Enliven Therapeutics, Inc. (ELVN) Operating cash flow 2019–2025
Enliven Therapeutics, Inc. (ELVN) annual operating cash flow history from SEC filings — net cash provided by operating activities each fiscal year.
-$70.3MFY2025 · since FY2019: -$21.9M → -$70.3M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$70.3M | +3.9% |
| FY2024 | -$73.2M | -19.5% |
| FY2023 | -$61.3M | -91.0% |
| FY2022 | -$32.1M | -67.6% |
| FY2021 | -$19.1M | +48.8% |
| FY2020 | -$37.4M | -70.9% |
| FY2019 | -$21.9M | — |
Source: SEC XBRL filings · For reference only · Not investment advice